Skip to main content
padlock icon - secure page this page is secure

Impact of HLA Haplotype on the Response to Antipsychotic Treatment of Schizophrenia

Buy Article:

$68.00 + tax (Refund Policy)

The response to antipsychotic drugs could be one attempt to develop a candidate phenotype of schizophrenia and deconstruct the illness for genetic analysis. This review discusses six studies on the association between HLA and the response to antipsychotic drugs. Three studies implicate an association between class I antigens. However, there are considerable limitations due to the small sample size, the different genetic backgrounds of the study subjects, varying diagnostic criteria, lack of standard criteria for drug response or refractoriness, inappropriate statistical methodology and varying HLA typing methods. Only for HLA-A1 was an association with response to standard neuroleptic treatment found repeatedly, indicating that the presence of HLA-A1 could predict a poorer outcome with conventional neuroleptic treatment. An association between HLA specificity and antipsychotic drug response may represent linkage disequilibrium with genes predisposing to schizophrenia on chromosome 6. Further studies are warranted with larger sample sizes in ethnically homogeneous populations, and standard criteria should be used for characterising the subjects.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: antipsychotic; antipsychotic drugs; hla haplotype; homogeneous populations

Document Type: Review Article

Affiliations: Department of Pathology, Haartman Institute, University of Helsinki and HUCH, Laboratory Diagnostics, P.O. Box 21 (Haartmaninkatu 3), FIN-00014, Helsinki, Finland.

Publication date: June 1, 2004

More about this publication?
  • Current Pharmacogenomics provides comprehensive overviews of all current research on pharmacogenomics and pharmacogenetics. All areas of the field from pre-clinical to clinical research are covered, including related areas such as genomics, proteomics, target discovery, bioinformatics and novel diagnostics. This international journal is peer-reviewed and publishes both mini- and full review articles.

    The journal has become essential reading for all researchers and clinicians with interests in pharmacogenomics and pharmacogenetics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more